Furthermore, ulocuplumab, an anti-CXCR4 monoclonal antibody (mAb), modifies the RNA expression of signals that mediate EMT, reducing tumor size and tumor BM homing [92]. The gene discussed is CXCR4; the disease is neoplasm.